Biotech Beach Bum

Disappointing results for Amgen’s Vectibix, which succeeded at reducing tumors for colon cancer patients with normal KRAS genes but failed to help them live longer. This trial was a landmark for the “personalized medicine” approach of using genetic biomarkers to identify which patients can effectively use a drug, and the trial’s failure may cast the whole approach into question.

 http://www.xconomy.com/seattle/2009/08/17/amgen-personalized-trial-shows-mixed-result/